HQL
Tekla Life Sciences Investors
18.20$
+4.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q3 23 | Q1 25 | Q3 25 | Q1 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -75.0% | -100.0% | |
| – | – | – | – | – | – | – | – | – | – | +374.5% | -51.1% | |
| – | – | – | – | – | – | – | – | – | – | – | -42.6% | |
| – | – | – | – | – | – | – | – | – | – | +175.9% | -28.5% | |
| – | – | – | – | – | – | – | – | -91.5% | – | – | -200.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.